This year will mark the fifth renewal by Congress, and it is widely agreed that the prescription drug user fee agreements will provide for the timely review of new drug and new bio...
This should have been an ongoing exercise over the last decade, in my opinion.
I also want to take a minute to applaud my friend from Oregon, Rep. Schrader, and Rep. Bilirakis, for working together o...
It is important. I am glad we are able to come together in a bipartisan fashion to make this happen.
Reauthorizing improved generic and biosimilar user fee programs will lead to timelier approvals and lower drug costs. It...
We must remain vigilant in ensuring government does not get in the way of the very innovation that can keep us safe.
When I was Chairman of the Commerce, Manufacturing, and Trade Subcommittee we dedicated a lot of time to self-driving ca...
I was frozen out by the then-chairman of this committee, Henry Waxman.
I contacted the transition team in 2008 and I said, 'Look, I didn't give up a 25-year medical career to come sit on the ...
I think we should have.
If it was working perfectly, if it was working perfectly we wouldn't be here today.